FrancophonIA/ELRC3.0 huggingface dataset:
English: The CHMP decided that Cerezyme gives effective control of the non-neurological symptoms of types 1 and 3 Gaucher disease.
Estonian: Inimravimite komitee otsustas, et Cerezyme võimaldab I ja III tüüpi Gaucher' tõve mitteneuroloogilisi sümptomeid efektiivselt leevendada.
English: It contains the active substance imiglucerase.
Estonian: Cerezyme sisaldab toimeainena imiglütseraasi.
English: Cerezyme is used in patients who have type 1 Gaucher disease, which does not affect the nerve cells, or type 3 Gaucher disease, which progresses slowly and affects the nerve cells.
Estonian: Cerezymet kasutatakse I tüüpi Gaucher' tõvega (ei mõjuta närvirakke) ja pikaajaliselt kulgeva III tüüpi Gaucher' tõvega (mõjutab närvirakke) patsientide raviks.
English: What benefit has Cerezyme shown during the studies?
Estonian: Milles seisneb uuringute põhjal Cerezyme kasulikkus?
English: • bone disease;
Estonian: • luuhaigus;
English: How does Cerezyme work?
Estonian: Kuidas Cerezyme toimib?
English: How is Cerezyme used?
Estonian: Kuidas Cerezymet kasutatakse?
English: What is Cerezyme used for?
Estonian: Milleks Cerezymet kasutatakse?
English: How has Cerezyme been studied?
Estonian: Kuidas Cerezymet uuriti?
English: 1 bottle
Estonian: 1 pudel
English: EU/1/11/692/001 Yellox
Estonian: EU/1/11/692/001
English: Ocular use bottle (PE) 5 ml
Estonian: Pudel (PE) 5 ml
English: Packaging Content (concentration)
Estonian: Pakendi sisu (kontsentratsioo n)
English: 0.9 mg/ml
Estonian: Yellox mg/ml
English: (Invented) name
Estonian: Ravimi (väljamõeldud) nimetus
English: Eye drops, solution
Estonian: Silmatilgad, lahus
English: EU Number Invented Name
Estonian: EL number Nimi
English: Content Package size Withdrawal Period
Estonian: Sisu Pakendi suurus Keeluaeg
English: Strength Pharmaceutical Form
Estonian: Farmatseutiline vorm
English: Target species
Estonian: Loomalii gid
English: Packaging
Estonian: Manustamisviis Pakend
English: This summary was last updated in 11-2013.
Estonian: Kokkuvõtte viimane uuendus: 11-2013.
English: Mixtard is given 30 minutes before a meal.
Estonian: Mixtardi manustatakse 30 minutit enne sööki.
English: The usual dose is between 0.3 and 1.0 international units (IU) per kilogram body weight per day.
Estonian: Tavaline annus on 0,3-1,0 rahvusvahelist ühikut (IU) kehakaalu kilogrammi kohta ööpäevas.
English: The full EPAR for Mixtard can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Mixtardi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What measures are being taken to ensure the safe and effective use of Mixtard?
Estonian: Mis meetmed võetakse, et tagada Mixtardi ohutu ja efektiivne kasutamine?
English: A risk management plan has been developed to ensure that Mixtard is used as safely as possible.
Estonian: Töötati välja riskijuhtimisstrateegia, et tagada Mixtardi võimalikult ohutu kasutamine.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Mixtard on 7 October 2002.
Estonian: Euroopa Komisjon andis Mixtardi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 7. oktoobril
English: Other information about Mixtard
Estonian: Muu teave Mixtardi kohta
English: It is usually given once or twice a day when a rapid initial effect together with a more long-lasting effect is needed.
Estonian: Mixtardi manustatakse tavaliselt üks või kaks korda ööpäevas, kui on vaja üheaegselt nii kiiret esmatoimet kui ka pikaajalist toimet.
English: Mixtard human insulin
Estonian: Mixtard iniminsuliin
English: The patient's blood glucose (sugar) should be tested regularly to find the lowest effective dose.
Estonian: Patsiendi vere glükoosisisaldust tuleb regulaarselt kontrollida, et leida vähim efektiivne annus.
English: This is a summary of the European public assessment report (EPAR) for Mixtard.
Estonian: See on ravimi Mixtard Euroopa avaliku hindamisaruande kokkuvõte.
English: By controlling the blood glucose, the symptoms and complications of diabetes are reduced.
Estonian: Vere glükoosisisalduse reguleerimise tulemusena vähenevad diabeedi sümptomid ja tüsistused.
English: The most common side effect with Mixtard (seen in more than 1 patient in 10) is hypoglycaemia (low blood glucose levels).
Estonian: Mixtardi kõige sagedam kõrvalnäht (esinenud enam kui 1 patsiendil 10st) on hüpoglükeemia (vere vähene glükoosisisaldus).
English: The CHMP decided that Mixtard's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee järeldas, et Mixtardi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Mixtard, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Strateegiast lähtudes lisati ravimi omaduste kokkuvõttesse ja pakendi infolehele Mixtardi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Mixtard, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Mixtardiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Mixtard was effective for both type 1 and type 2 diabetes.
Estonian: Mixtard oli efektiivne nii I kui ka II tüüpi diabeedi korral.
English: Diabetes is a disease in which the body does not produce enough insulin to control the blood glucose or when the body is unable to use insulin effectively.
Estonian: Diabeet (suhkurtõbi) on haigus, mille korral organismis ei teki vere glükoosisisalduse reguleerimiseks piisavalt insuliini või organism ei suuda insuliini efektiivselt kasutada.
English: Mixtard has been studied in a total of 294 patients with type 1 diabetes, when the pancreas cannot produce insulin, and type 2 diabetes, when the body is unable to use insulin effectively.
Estonian: Mixtardi uuriti kokku 294 patsiendil, sealhulgas I tüüpi diabeediga patsiendid, kelle kõhunääre ei suuda toota insuliini, ja II tüüpi diabeediga patsiendid, kelle organism ei suuda insuliini tõhusalt kasutada.
English: About onethird of the patients had type 1 diabetes and the remainder had type 2 diabetes.
Estonian: I tüüpi diabeet oli ligikaudu kolmandikul patsientidest, ülejäänutel oli II tüüpi diabeet.
English: Mixtard contains insulin in two forms: a soluble form, which acts quickly (within 30 minutes of injection) and an ‘isophane', form which is absorbed much more slowly during the day.
Estonian: Mixtard sisaldab insuliini kahel kujul: lahustuv insuliin, mis toimib kiiresti (30 minuti jooksul pärast süstimist), ja isofaaninsuliin, mis imendub ööpäeva jooksul palju aeglasemalt.
English: Mixtard is used to treat diabetes.
Estonian: Mixtardi kasutatakse diabeedi raviks.
English: This gives Mixtard a longer duration of action.
Estonian: See pikendab Mixtardi toimeaega.
English: What is Mixtard?
Estonian: Mis on Mixtard?
English: The replacement insulin acts in same way as naturally produced insulin and helps glucose enter cells from the blood.
Estonian: Asendusinsuliin toimib samal viisil kui organismis tekkiv insuliin, aidates glükoosil siseneda verest rakkudesse.
English: HbA1c gives an indication of how well the blood glucose is controlled.
Estonian: HbA1c näitab vere glükoosisisalduse reguleeritavust.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Mixtard.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For the full list of all side effects and restrictions, see the package leaflet.
Estonian: Mixtardi kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Why has Mixtard been approved?
Estonian: Miks Mixtard heaks kiideti?
English: The active substance in Mixtard, human insulin, is produced by a method known as ‘recombinant technology': the insulin is made by a yeast cells into which a gene (DNA) has been introduced, which makes them able to produce insulin.
Estonian: Mixtardi toimeainet iniminsuliini valmistatakse rekombinant-DNA-tehnika abil: insuliini toodab pärm, millele on lisatud insuliini teket võimaldav geen (DNA).
English: What is the risk associated with Mixtard?
Estonian: Mis riskid Mixtardiga kaasnevad?
English: Mixtard led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with other human insulin.
Estonian: Mixtard vähendas HbA1c sisaldust, mis näitas, et organism reguleeris vere glükoosisisaldust sarnasel määral kui iniminsuliin.
English: Mixtard is a suspension for injection that contains the active substance human insulin.
Estonian: Mixtard on süstesuspensioon, mis sisaldab toimeainena iniminsuliini.
English: It is available as vials, cartridges (Penfill) or pre-filled pens (InnoLet or FlexPen).
Estonian: Seda turustatakse viaalides, kolbampullides (PenFill) ja eeltäidetud pensüstaldes (InnoLet ja FlexPen).
English: Mixtard is given by injection under the skin, in the thigh, the abdominal wall (at the front of the waist), the gluteal region (buttocks) or the deltoid region (shoulder).
Estonian: Mixtardi manustatakse nahaaluse süstina reiepiirkonda, kõhuseina, tuharatesse või deltalihase piirkonda (õlalihasesse).
English: Mixtard is a replacement insulin which is very similar to the insulin made by the pancreas.
Estonian: Mixtard on asendusinsuliin, mis on väga sarnane kõhunäärmes tekkiva insuliiniga.
English: The study compared Mixtard 30 to a similar mix, but made up using an insulin analogue (insulin aspart).
Estonian: Uuring võrdles ravimit Mixtard 30 sarnase seguga, mis sisaldas insuliini analoogi (aspartinsuliini).
English: What benefit has Mixtard shown during the studies?
Estonian: Milles seisneb uuringute põhjal Mixtardi kasulikkus?
English: The injection site should be changed for each injection.
Estonian: Iga süst tehakse eri kohta.
English: The study measured the level of glycosylated haemoglobin (HbA1c) after 12 weeks, which is the percentage of haemoglobin in the blood that has glucose attached.
Estonian: Uuringus mõõdeti vere glükoseerunud hemoglobiini sisaldust (HbA1c; hemoglobiin, millele on kinnitunud glükoos) pärast 12-nädalast ravi.
English: Mixtard contains both fast-acting (soluble) and long-acting (isophane) insulin:
Estonian: Mixtard sisaldab nii kiiretoimelist (lahustuvat) kui ka pikatoimelist (isofaan-)insuliini.
English: How does Mixtard work?
Estonian: Kuidas Mixtard toimib?
English: How is Mixtard used?
Estonian: Kuidas Mixtardi kasutatakse?
English: What is Mixtard used for?
Estonian: Milleks Mixtardi kasutatakse?
English: How has Mixtard been studied?
Estonian: Kuidas Mixtardi uuriti?
English: 10 July 2017
Estonian: 10. juuli 2017
English: The European Commission issued a decision on 10 July 2017.
Estonian: Euroopa Komisjoni tegi otsuse 10. juulil 2017.
English: Outcome of a referral procedure under Article 35 of Directive 2001/82/EC (EMEA/V/A/121)
Estonian: Direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse (EMEA/V/A/121) tulemused
English: On 22 June 2016, Finland initiated a referral procedure under Article 35 of Directive 2001/82/EC for the aforementioned veterinary medicinal products.
Estonian: 22. juunil 2016 algatas Soome direktiivi 2001/82/EÜ artikli 35 kohase esildismenetluse eespool nimetatud veterinaarravimite kohta.
English: Tylosin is a macrolide antibiotic and is active mostly against Gram-positive bacteria and mycoplasmas.
Estonian: Tülosiin on makroliidantibiootikum ja see toimib peamiselt gram-positiivsete bakterite ja mükoplasmade vastu.
English: Finland considered that ineffective treatment of mycoplasma mastitis with tylosin presents a serious concern to animal and public health as it delays the correct diagnosis, enables spread of the pathogen to other cows, impedes efficient/prudent control measures and increases risk for the development of antimicrobial resistance due to unnecessary use of antimicrobials.
Estonian: Soome oli arvamusel, et mükoplasma põhjustatud mastiidi ebaefektiivne ravi on oluline looma- ja rahvatervise probleem, sest see lükkab edasi õiget diagnoosi ja võimaldab patogeenil levida teistele lehmadele, takistab efektiivseid/arukaid nakkustõrjemeetmeid ja suurendab antimikroobsete ainete ebavajaliku kasutamise tõttu antimikroobse resistentsuse tekkeriski.
English: Tylosin and its phosphate and tartrate salts are used in veterinary medicines for treatment of conditions caused by sensitive organisms.
Estonian: Tülosiini ning selle fosfaat- ja tartraatsooli kasutatakse toiduloomaliikidel neile ainetele tundlike organismide tekitatud seisundite raviks.
English: The Committee recommended variations to the terms of the marketing authorisations for the aforementioned veterinary medicinal products in order to remove the indications ‘bovine mastitis caused by Mycoplasma spp.'
Estonian: Komitee soovitas muuta eespool nimetatud veterinaarravimite müügilubade tingimusi ja eemaldada ravimiteabest näidustused „Mycoplasma spp.
English: Based on the evaluation of the currently-available data, the CVMP concluded that, in the absence of specific pre-clinical or clinical data, and in light of the current scientific knowledge, the indication for treatment of bovine mastitis caused by Mycoplasma spp.
Estonian: Tuginedes praegu kättesaadavate andmete hindamisele, otsustas veterinaarravimite komitee, et spetsiifiliste prekliiniliste ja kliiniliste andmete puudumise tõttu ja praegusi teaduslikke andmeid arvestades ei saa toetada tülosiini sisaldavate veterinaarravimite näidustust Mycoplasma spp.
English: In the absence of submitted proprietary pre-clinical or clinical data for the products in the scope of this referral in support of the respective indication, the CVMP considered scientific references on efficacy.
Estonian: Arvestades seda, et asjaomase näidustuse toetuseks ei esitatud selle menetlusega hõlmatud ravimpreparaatide kohta ettevõtetesiseseid prekliinilisi ega kliinilisi andmeid, analüüsis veterinaarravimite komitee teaduslikke viiteid efektiivsuse kohta.
English: What is tylosin?
Estonian: Mis on tülosiin?
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that, in the absence of pre-clinical or clinical data, treatment of bovine mastitis caused by Mycoplasma spp.
Estonian: Ameti veterinaarravimite komitee järeldas, et prekliiniliste ja kliiniliste andmete puudumise tõttu ei ole eespool nimetatud veterinaarravimid efektiivsed Mycoplasma spp.
English: On 16 March 2017, the European Medicines Agency (the Agency) completed a review of the effectiveness of veterinary medicinal products containing tylosin that are administered parenterally and intended for the treatment of bovine mastitis caused by Mycoplasma spp.
Estonian: 16. märtsil 2017 lõpetas Euroopa Ravimiamet (amet) Mycoplasma spp.
English: The CVMP was requested to review all available data and to provide its opinion on whether the indication related to 'bovine mastitis caused by Mycoplasma spp.'
Estonian: Veterinaarravimite komiteel paluti läbi vaadata kõik olemasolevad andmed ja väljastada arvamus selle kohta, kas Mycoplasma spp.
English: or ‘bovine mastitis caused by Mycoplasma bovis' from the product information.
Estonian: põhjustatud veiste mastiit“ ja „Mycoplasma bovis'e põhjustatud veiste mastiit“.
English: with veterinary medicinal products containing tylosin which are administered parenterally is not supported.
Estonian: põhjustatud veiste mastiidi raviks ette nähtud tülosiini sisaldavad parenteraalsed veterinaarravimid?
English: The CVMP recommended deletion of the indications related to ‘bovine mastitis caused by Mycoplasma spp.'
Estonian: Veterinaarravimite komitee soovitas asjaomaste ravimpreparaatide ravimiteabest kustutada näidustused, mis on seotud Mycoplasma spp.
English: MA (EU) number
Estonian: Müügiloa (EL) number
English: Strength Pharmaceutical form
Estonian: Tugevus Ravimvorm Manustamisviis Sisepakendi iseloomustus Pakendi suurus
English: Ref.: EMEA/632126/2009 EMEA/H/C/974
Estonian: Viide: EMEA/632126/2009 EMEA/H/C/974
English: The best dose to use in these patients has not yet been determined.
Estonian: Nendel patsientidel kasutatav parim annus ei ole veel kindlaks määratud.
English: Clopidogrel BMS clopidogrel
Estonian: Clopidogrel BMS klopidogreel
English: The European Commission granted a marketing authorisation valid throughout the European Union for Clopidogrel BMS to Bristol Myers Squibb Pharma EEIG on 16 July 2008.
Estonian: Euroopa Komisjon andis Clopidogrel BMS-i müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Bristol Myers Squibb Pharma EEIG 16. juulil 2008.
English: This authorisation was based on the authorisation granted to Iscover in 1998 (‘informed consent').
Estonian: Müügiluba põhineb 1998. aastal antud Iscoveri müügiloal (teabel põhineva nõusoleku alusel).
English: It must not be used in patients who have severe liver disease or a disease that may cause bleeding.
Estonian: ei tohi kasutada patsiendid, kellel on raske maksahaigus või haigus, mis võib põhjustada verejookse.
English: There was also a reduction in the patients who had a stent inserted.
Estonian: Vähenemine esines ka stendiga patsientidel.
English: The main measure of effectiveness was how many patients experienced a new ‘ischaemic event' (heart attack, ischaemic stroke or death) over one to three years.
Estonian: Efektiivsuse põhinäitaja oli arv, mitmel patsiendil tekkis uus isheemianäht (südameinfarkt, isheemiline insult või surm) ühe kuni kolme aasta jooksul.
English: Clopidogrel BMS can be started between seven days and six months after the
Estonian: Clopidogrel BMS-i manustamist võib alustada seitsme päeva kuni kuue kuu jooksul pärast
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part
Estonian: Kui soovite lisateavet inimravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande osa).
English: It is available as pink tablets (round: 75 mg; oblong: 300 mg).
Estonian: Seda turustatakse roosade tablettidena (ümmargused 75 mg, piklikud 300 mg).
English: For the full list of restrictions, see the Package Leaflet.
Estonian: Piirangute täieliku loetelu leiate pakendi
English: Clopidogrel BMS can be given to the following groups of patients:
Estonian: Clopidogrel BMS-i võib kasutada järgmiste patsiendirühmade korral:
English: • patients with peripheral arterial disease (problems with blood flow in the arteries);
Estonian: • perifeersete arterite haigusega (arteriverevoolu probleemiga) patsiendid;
English: In acute coronary syndrome, Clopidogrel BMS is used together with aspirin and treatment generally starts with a loading dose of one 300-mg tablet or four 75-mg tablets.
Estonian: Akuutse koronaarsündroomi korral kasutatakse Clopidogrel BMS-i koos aspiriiniga; ravi algab üldiselt küllastusannusega, kus võetakse üks 300 mg tablett või neli 75 mg tabletti.
English: This showed that Clopidogrel BMS reduces the risk of an event.
Estonian: See näitas, et Clopidogrel BMS vähendab nähtude tekke riski.
English: The standard dose of Clopidogrel BMS is one 75-mg tablet once a day, taken with or without food.
Estonian: Clopidogrel BMS-i tavaannus on üks 75 mg tablett üks kord ööpäevas koos toiduga või ilma.
English: The Committee recommended that Clopidogrel BMS be given marketing authorisation.
Estonian: Komitee soovitas anda Clopidogrel BMS-ile müügiloa.
English: This is then followed by the standard 75-mg dose once a day for at least four weeks (in ST segment elevation myocardial infarction) or for up to 12 months (in non-ST segment elevation syndrome).
Estonian: Seejärel jätkatakse tavalise annusega 75 mg ööpäevas vähemalt neli nädalat (ST-segmendi elevatsiooniga infarkti korral) või kuni 12 kuud (ST-segmendi elevatsiooni puudumise korral).
English: In non-ST segment elevation acute coronary syndrome, the overall relative reduction in the risk of an event compared with placebo was 20%.
Estonian: ST-segmendi elevatsioonita ägeda koronaarsündroomi korral oli nähtude tekke üldine suhteline risk 20% väiksem kui platseebo korral.
English: Clopidogrel BMS was more effective than aspirin at preventing new ischaemic events.
Estonian: Clopidogrel BMS oli uute isheemianähtude ennetamisel aspiriinist efektiivsem.
English: For genetic reasons, some patients may not be able to convert Clopidogrel BMS as effectively as others, which could reduce their response to the medicine.
Estonian: Geneetilistel põhjustel ei suuda kõikide patsientide organism Clopidogrel BMS-i edukalt muundada, mis võib nende ravivastust vähendada.
English: In the studies of acute coronary syndrome, all of the patients also took aspirin and the main measure of effectiveness was the number of patients experienced an ‘event' such as a blocked artery, another heart attack or death during the
Estonian: Ägeda koronaarsündroomi uuringutes manustasid kõik patsiendid ka aspiriini ja efektiivsuse põhinäitaja oli nende patsientide arv, kellel esines uuringu ajal teatud näht nagu arteriummistus, uus südameinfarkt
English: This stops the platelets becoming ‘sticky', reducing the risk of a blood clot forming and helping to prevent another heart attack or stroke.
Estonian: Vereliistakud ei muutu enam kleepuvaks ja väheneb trombide tekke oht, millega ennetatakse järgmist südameinfarkti või insulti.
English: The Committee for Medicinal Products for Human Use (CHMP) decided that Clopidogrel BMS's benefits are greater than its risks in adults for the prevention of atherothrombotic events.
Estonian: Inimravimite komitee otsustas, et Clopidogrel BMS-i kasulikkus täiskasvanute aterotrombootiliste nähtude ennetamisel on suurem kui sellega kaasnevad riskid.
English: Clopidogrel BMS can be started between a few days and 35 days after the attack;
Estonian: Clopidogrel BMS-i manustamist võib alustada mõne kuni 35 päeva jooksul pärast infarkti;
English: Clopidogrel BMS is converted into its active form in the body.
Estonian: Clopidogrel BMS muundub organismis aine aktiivseks vormiks.
English: Clopidogrel BMS has been compared with aspirin in a study called CAPRIE including around 19,000 patients who had recently had a heart attack or an ischaemic stroke, or who had established peripheral arterial disease.
Estonian: Clopidogrel BMS-i võrreldi aspiriiniga uuringus (CAPRIE), milles osales ligikaudu 19 000 patsienti, kellel oli hiljuti olnud südameinfarkt või isheemiline insult või väljakujunenud perifeersete arterite haigus.
English: Clopidogrel BMS should not be used in people who may be hypersensitive (allergic) to clopidogrel or any of the other ingredients.
Estonian: Clopidogrel BMS-i ei tohi kasutada patsiendid, kes võivad olla klopidogreeli või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: The most common side effects with Clopidogrel BMS (seen in between 1 and 10 patients in 100) are haematoma (a collection of blood under the skin), epistaxis (nosebleeds), gastrointestinal haemorrhage (bleeding in the stomach or gut), diarrhoea, abdominal pain (stomach ache), dyspepsia (heartburn), bruising and bleeding where the skin is punctured.
Estonian: Clopidogrel BMS-i kõige sagedamad kõrvalnähud (esinenud ühel kuni kümnel patsiendil sajast) on hematoom (verevalum), epistaksis (ninaverejooks), seedekulgla hemorraagia (verejooks maos või sooles), kõhulahtisus, kõhuvalu, düspepsia (kõrvetised) ning verevalumid ja veritsemine süstekohal.
English: • patients who have had a recent ischaemic stroke (stroke caused by the failure of the blood supply to part of the brain).
Estonian: • patsiendid, kellel on hiljuti olnud isheemiline insult (aju teatud osa verevarustushäiretest tingitud insult).